tetano
Editor, Senior Moderator
Vaccine
. 2024 Jun 4:S0264-410X(24)00623-6.
doi: 10.1016/j.vaccine.2024.05.055. Online ahead of print. Costs of in- and outpatient respiratory disease and the seasonal influenza vaccination program in Armenia - 2020-2021
Stacie Gobin[SUP] 1 [/SUP], Gayane Sahakyan[SUP] 2 [/SUP], Michael Kusi Appiah[SUP] 3 [/SUP], Ani Manukyan[SUP] 2 [/SUP], Karo Palayan[SUP] 2 [/SUP], Malembe Ebama[SUP] 4 [/SUP], Artavazd Vanyan[SUP] 2 [/SUP], Margaret McCarron[SUP] 5 [/SUP], Joseph Bresee[SUP] 4 [/SUP]
Affiliations
Background: Despite the substantial global impact of influenza, there are limited economic data to guide influenza vaccination programs investments in middle-income countries. We measured the costs of influenza and the costs of an influenza vaccination program in Armenia, using a societal perspective.
Methods: During December 2022 through March 2023, retrospective cost data were collected from case-patients and healthcare providers through structured questionnaires at 15 healthcare facilities selected through stratified sampling. Medical costs included medications, laboratory costs, laboratory and diagnostic tests, and routine health care service costs and direct and indirect societal costs were included. Vaccination program costs from the 2021-2022 influenza season were identified using accounting records and categorized as: planning, distribution, training, social mobilization and outreach, supervision and monitoring, procurement, and national- and facility-level administration and storage.
Results: The mean costs per episode for SARI and ILI case-patients were $US 823.6 and $US 616.57, respectively. Healthcare service costs were the largest direct expenses for ILI and SARI case-patients. Total costs of the 2021-2022 influenza vaccination program to the government were $US 4,353,738, with the largest costs associated with national- and facility-level administration and storage (30% and 65% respectively). The total cost per dose administered was $US 25.61 ($US 7.73 per dose for procurement and $US 17.88 for the marginal administration cost per dose).
Conclusions: These data on the costs of seasonal influenza prevention programs and the societal costs of influenza illness in Armenia may inform national vaccine policy decisions in Armenia and may be useful for other middle-income countries. Influenza vaccines, like other vaccine programs, are recognized as substantially contributing to the reduction disease burden and associated mortality and further driving economic growth. However, a formal cost-effectiveness analysis should be performed once burden of disease data are available.
Keywords: Armenia; Cost-effectiveness; Costing; Influenza; Vaccination; Vaccination program.
. 2024 Jun 4:S0264-410X(24)00623-6.
doi: 10.1016/j.vaccine.2024.05.055. Online ahead of print. Costs of in- and outpatient respiratory disease and the seasonal influenza vaccination program in Armenia - 2020-2021
Stacie Gobin[SUP] 1 [/SUP], Gayane Sahakyan[SUP] 2 [/SUP], Michael Kusi Appiah[SUP] 3 [/SUP], Ani Manukyan[SUP] 2 [/SUP], Karo Palayan[SUP] 2 [/SUP], Malembe Ebama[SUP] 4 [/SUP], Artavazd Vanyan[SUP] 2 [/SUP], Margaret McCarron[SUP] 5 [/SUP], Joseph Bresee[SUP] 4 [/SUP]
Affiliations
- PMID: 38839517
- DOI: 10.1016/j.vaccine.2024.05.055
Background: Despite the substantial global impact of influenza, there are limited economic data to guide influenza vaccination programs investments in middle-income countries. We measured the costs of influenza and the costs of an influenza vaccination program in Armenia, using a societal perspective.
Methods: During December 2022 through March 2023, retrospective cost data were collected from case-patients and healthcare providers through structured questionnaires at 15 healthcare facilities selected through stratified sampling. Medical costs included medications, laboratory costs, laboratory and diagnostic tests, and routine health care service costs and direct and indirect societal costs were included. Vaccination program costs from the 2021-2022 influenza season were identified using accounting records and categorized as: planning, distribution, training, social mobilization and outreach, supervision and monitoring, procurement, and national- and facility-level administration and storage.
Results: The mean costs per episode for SARI and ILI case-patients were $US 823.6 and $US 616.57, respectively. Healthcare service costs were the largest direct expenses for ILI and SARI case-patients. Total costs of the 2021-2022 influenza vaccination program to the government were $US 4,353,738, with the largest costs associated with national- and facility-level administration and storage (30% and 65% respectively). The total cost per dose administered was $US 25.61 ($US 7.73 per dose for procurement and $US 17.88 for the marginal administration cost per dose).
Conclusions: These data on the costs of seasonal influenza prevention programs and the societal costs of influenza illness in Armenia may inform national vaccine policy decisions in Armenia and may be useful for other middle-income countries. Influenza vaccines, like other vaccine programs, are recognized as substantially contributing to the reduction disease burden and associated mortality and further driving economic growth. However, a formal cost-effectiveness analysis should be performed once burden of disease data are available.
Keywords: Armenia; Cost-effectiveness; Costing; Influenza; Vaccination; Vaccination program.